Development of vaccines for SARS-CoV-2

F1000Res. 2020 Aug 17:9:F1000 Faculty Rev-991. doi: 10.12688/f1000research.25998.1. eCollection 2020.

Abstract

COVID-19 emerged in late 2019 and has rapidly spread through many countries globally. The causative SARS-CoV-2 virus was not known until recently, and there is little or no natural immunity in human populations. There is an urgent need for vaccines and drugs to combat this new pandemic. In just a few months, huge efforts and resources by government, academia, and industry have been thrown into the race to develop a vaccine. This brief review summarizes and discusses the array of technologies being applied to vaccine development, highlighting the strengths and weaknesses of the various approaches.

Keywords: COVID-19; SARS-CoV-2; Vaccines.

Publication types

  • Review

MeSH terms

  • Betacoronavirus
  • COVID-19
  • COVID-19 Vaccines
  • China
  • Clinical Trials as Topic
  • Coronavirus Infections / prevention & control*
  • Humans
  • Pandemics / prevention & control*
  • Pneumonia, Viral / prevention & control*
  • SARS-CoV-2
  • Spike Glycoprotein, Coronavirus
  • Viral Vaccines*

Substances

  • COVID-19 Vaccines
  • Spike Glycoprotein, Coronavirus
  • Viral Vaccines
  • spike protein, SARS-CoV-2

Grants and funding

SM is the recipient of a National Health and Medical Research Council (NHMRC) Senior Research Fellowship (APP11544347).